Results 41 to 50 of about 29,134 (219)

Pregnancy and atypical antipsychotics.

Psychiatria Danubina, 2009
Scientific research aiming at discovering new generations of effective medications is a common practice in medicine, and psychiatric research is no exception. Antipsychotics are used to treat chronic mental illnesses such as schizophrenia. The new generation of antipsychotics (atypicals) gradually reveal their advantages in comparison to the older ...
Ružić, Klementina, Dadić-Hero, Elizabeta, Knez, Rajna, Medved, Paola, Petrić, Daniela   +4 more
openaire   +3 more sources

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study (PREMANDYSK)

Movement Disorders, EarlyView.
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol, Fabienne Ory‐Magne, Wassilios G. Meissner, David Maltête, Luc Defebvre, Jean‐Philippe Azulay, Stéphane Thobois, Jean‐Luc Houeto, Claire Thalamas, Agnès Sommet, Christian Geny, Philippe Damier, Mathieu Anheim, Ana Marquès, François Viallet, Maurice Giroud, Romain Lefaucheur, Guillaume Costentin, Umberto Spampinato, Alexandra Samier‐Foubert, Nicolas Carrière, Eugénie Mutez, Louise‐Laure Mariani, Alexandre Eusebio, Stéphane Prange, Isabelle Benatru, Mahmoud Charif, Christine Brefel‐Courbon, Margherita Fabbri, Monique Galitzky, Vanessa Rousseau, Amandine Saubion, Hélène Catala, Joaquim J. Ferreira, David J. Burn, Jean‐Christophe Corvol, on behalf of the PREMANDYSK Study Group, Olivier Rascol, Fabienne Ory‐Magne, Claire Thalamas, Jean‐Christophe Corvol, Luc Defebvre, Wassilios G Meissner, David Maltête, Jean‐Philippe Azulay, Jean‐Luc Houeto, Stéphane Thobois, François Viallet, Alexandra Samier‐Foubert, Umberto Spampinato, Thomas Boraud, François Tison, Franck Durif, Ana Marques, Bérengère Debilly, Stéphane Bernard, Maurice Giroud, Nicolas Carrière, Eugénie Mutez, Frederic Torny, Philippe Couratier, Oliver Colin, Thomas Gaudin, Pierre Boutet, Emmanuel Broussolle, Stéphane Prange, Cathrine Caire, Hélène Merle, Alexandre Eusebio, Manel Nouira, Christian Geny, Mahmoud Charif, Philippe Damier, Pascal Derkinderen, Mirela Faighel, Violaine Talmant, Severine LeDily, Louise‐Laure Mariani, Lucette Lacomblez, Anne‐Marie Bonnet, Isabelle Benatru, Jean‐Luc Houeto, Solène Ansquer, Emilie Rabois, Anne Fradet, Romain Lefaucheur, Guillaume Costentin, Linda Vernon, Christine Tranchant, Matthieu Anheim, Ouhaid Lagha‐Boukbiza, Thomas Wirth, Agnès Sommet, Vanessa Rousseau, Hélène Catala, Monique Galiztky, Amandine Saubion, Christine Brefel‐Courbon, Margherita Fabbri, Nadéra Ainaoui, Estelle Dellapina, Alexandra Salis, Frédéric Eyvrard, Camille Jurado, Nicolas Boulloche, Jany Rey‐Zermati, Jean Jaques Boulesteix   +106 more
wiley   +1 more source

Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression

Drug, Healthcare and Patient Safety, 2020
Farid Chekani,1 Holly M Holmes,2 Michael L Johnson,1 Hua Chen,1 Jeffrey T Sherer,1 Rajender R Aparasu1 1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX 77204-5047, USA; 2Division of ...
Chekani F, Holmes HM, Johnson ML, Chen H, Sherer JT, Aparasu RR   +5 more
doaj  

Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study

Movement Disorders, EarlyView.
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola, Marjaana Koponen, Valtteri Kaasinen, Jarmo Hietala, Sirpa Hartikainen, Anna‐Maija Tolppanen   +5 more
wiley   +1 more source

Lifetime Mixed Depression and Childhood Trauma in Individuals With Bipolar Disorders

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background and Aims Mixed Depression (MxD), characterized by the co‐occurrence of depressive and excitatory symptoms, is a prevalent yet often underdiagnosed presentation in bipolar disorders (BD), with significant implications for prognosis and treatment. Childhood trauma is a key environmental risk factor associated with a more severe course
Francesca Bardi, Mario Pinto, Alessio Simonetti, Marco Di Nicola, Marianna Mazza, Giovanni Manfredi, Georgios D. Kotzalidis, Gabriele Sani, Delfina Janiri   +8 more
wiley   +1 more source

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

BMC Psychiatry, 2005
Background Antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia. Simultaneous treatment with multiple antipsychotics (polypharmacy) is suggested by some expert consensus guidelines as the last resort after ...
Correll Christoph, Zhu Baojin, Ascher-Svanum Haya, Faries Douglas, Kane John   +4 more
doaj   +1 more source

Developing a Trauma Checklist for People With a Learning Disability Accessing Community Health and Support Services

British Journal of Learning Disabilities, EarlyView.
ABSTRACT Background Research suggests people with a learning disability experience high prevalence of adverse life events which may result in trauma‐related mental health conditions. Identifying trauma‐related mental health conditions can facilitate access to support, however research suggests they may be under‐identified in this group. The aim of this
Sarah Wigham, Arman Iranpour, John L. Taylor, Claire Hills‐Wilson, Pamela Reitemeier, Katharine Petersen, Iain McKinnon, Simon S. Hackett   +7 more
wiley   +1 more source

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US

ClinicoEconomics and Outcomes Research, 2013
Ken O'Day,1 Krithika Rajagopalan,2 Kellie Meyer,1 Andrei Pikalov,2 Antony Loebel21Xcenda, Palm Harbor, FL, 2Sunovion Pharmaceuticals, Marlborough, MA, USABackground: The purpose of this study was to evaluate the long-term cost-effectiveness ...
O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A   +4 more
doaj